Best Osteosarcoma Osteosarcoma in Israel: TOP 12 doctors

Prof. Merimsky heads the Unit of Soft Tissue and Bone Oncology at Sourasky Medical Center, specializing in sarcoma care since 1995.

• Fellowship-trained at Institut Gustave Roussy in Paris for sarcoma treatment
• ESMO Faculty member for soft tissue and bone sarcomas
• Over 41 years of experience leading Israel's premier orthopedic oncology unit
• Published research on tumor immunology and cancer-induced bone diseases

Dr. Yuri Goldes is a general surgeon with more than 20 years of clinical experience. He specializes in upper gastrointestinal and oncologic surgery. He is Deputy Director of the Department of General Surgery and Transplantation at Sheba Medical Center in Tel Aviv. He also leads the Upper GI Surgery Unit. He was named to Forbes Israel’s Best Doctors in 2025. He is ranked among Israel’s Best Gastrointestinal Surgeons by Forbes. In 2019, he received the Israeli Ministry of Health “Best Doctor of the Year” award.

He is an expert in advanced minimally invasive and robotic surgery. He treats diaphragmatic hernia, achalasia, GERD, and gallbladder disease. He also performs oncologic surgery for pancreatic, gastric, and esophageal cancers. He uses laparoscopic and robotic techniques.

He pioneered some of Israel’s first robotic oncologic resections of the stomach and pancreas. He is among a small group worldwide who perform minimally invasive Whipple procedures (pancreaticoduodenectomy) using advanced laparoscopy. He applies methods that improve outcomes and speed recovery. He provides personalized care.

Dr. Dror Levin is a leading expert in treating bone cancer (sarcoma) in children at Sourasky Medical Center.

• Director of children's hematology oncology department
• Specialized in pediatric hematology and oncology
• Studied bone oncology at Rizzoli Orthopaedic Institute in Italy
• Member of ISPHO – Israel's pediatric hemato-oncology association

Dr. Amir specializes in sarcoma treatment, with awards for excellence in surgical oncology and military medicine contributions.

• Expertise in osteosarcoma and five other sarcoma types
• Trained in orthopaedic oncology at National Cancer Institute, USA
• Member of three international sarcoma-focused societies (MSTS, CTOS, ISOLS)
• Recipient of research grants in sarcoma surgery and therapeutics

Professor Jakov Bikels heads the Department of Metastatic Bone Lesions at Tel Aviv's major Ichilov Medical Center. He brings deep academic and clinical expertise specifically for complex bone cancers.

• Specializes exclusively in orthopedic oncology
• Holds a professorship at Tel Aviv University's Faculty of Medicine
• Educated at the Hebrew University of Jerusalem
• Completed advanced internships in Israel and the United States
• Experienced Senior Doctor in Israeli oncological orthopedics centers

Chief Physician of the Oncology Center at Assuta Medical Center – specialized in osteosarcoma treatment.

• Leading oncologist at a top-tier medical facility
• Extensive experience in managing complex oncology cases
• Focuses on personalized treatment approaches

Orthopedic surgeon specializing in endoprosthetics – the artificial joint replacements often needed after complex bone tumor surgery.

• Expert in limb reconstruction and tumor removal surgery
• Focuses on joint replacement for musculoskeletal cancers
• Based at the Assuta Medical Center

Internationally recognized pediatric oncologist – Prof. Ben-Harush leads the Pediatric Division at Ruth Rappaport Children's Hospital, Rambam.

• Specializes in pediatric oncology and bone marrow transplantation
• Recipient of the Chevalier de la Legion d'Honneur award
• Named one of the world's most caring doctors by the World Medical Association
• Member of children's oncology groups in the USA and Europe

Head of the Pediatric Hematology Department – Sergei Postovskiy specializes in pediatric osteosarcoma surgery at Rambam Medical Center.

• Trained for pediatric-specific cases at specialized department
• Focuses on hematology surgical techniques for young patients
• Operates within dedicated department framework for consistent protocols
• Handles both routine and complex pediatric surgical needs

Dr. Netanel Meusher leads the bone cancer treatment team at Rambam Medical Center.

• Specialist in the treatment of bone cancer
• Head of the Department at a major Israeli hospital

Dr. Eytan Aharon Ben‑Ami, MD, is a Senior Physician in the Sarcoma and Bone Oncology Service at Sheba Medical Center. He heads the Oncology Division and the Early-Phase Clinical Trials Unit. He founded the Sheba Clinical Research Organization. He is an academic affiliate at Tel Aviv University.

He specializes in sarcomas and primary bone tumors, including soft tissue sarcoma, liposarcoma, leiomyosarcoma, and osteosarcoma. He leads Phase I trials in targeted therapy and immunotherapy. He designs personalized treatment plans for rare cancers. He also develops patient-centered programs, including pilots in advanced immunotherapy delivery.

He completed a fellowship in Sarcoma and Bone Oncology at the Dana-Farber Cancer Institute/Harvard Cancer Center. He has authored more than 40 publications on early detection, molecular and viral mechanisms, and new cancer therapies.

Professor Raanan Berger, MD PhD, is a medical oncologist and radiotherapist. He is Director of the Cancer Center at Sheba Medical Center and heads its clinical research unit. He was listed in Forbes Israel’s “Best Doctors” (2025). He leads the genitourinary oncology program with a focus on prostate cancer. His care includes systemic therapy and radiotherapy in a multidisciplinary, patient-centered model.

He is board-certified in oncology. He earned his MD and PhD at Tel Aviv University and completed his clinical training at Sheba. He then completed a postdoctoral fellowship at Dana-Farber/Harvard, focusing on prostate cancer with Dr. Philip Kantoff and molecular oncology in Dr. William C. Hahn’s lab. He is a member of ESMO and ASCO. He has co-authored more than 20 peer-reviewed papers, including studies on outcomes in high- versus very high-risk prostate cancer and on BRCA1/2 in large cohorts.